Gene therapy (AAV vector) · Gene replacement · developed by Neurocrine Biosciences
AAV2-hAADC is an adeno-associated virus serotype 2 gene therapy carrying the human aromatic amino acid decarboxylase (DDC) gene, delivered by intracerebral infusion. It is being studied in aromatic amino acid decarboxylase deficiency, a condition caused by a defect in that gene.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02926066 | Phase 2 | Aromatic Amino Acid Decarboxylase Deficiency | Completed | PTCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Aromatic Amino Acid Decarboxylase Deficiency